Pricing Log in Create free account

Decoy Therapeutics Inc (DCOY) vs VivoSim Labs, Inc. (VIVS)

Decoy Therapeutics Inc and VivoSim Labs, Inc. are both Biotechnology companies. Decoy Therapeutics Inc and VivoSim Labs, Inc. are of similar size ($2.9M and $2.8M). VivoSim Labs, Inc. has negative trailing earnings, so its P/E is not meaningful; Decoy Therapeutics Inc trades at 0.0×. VivoSim Labs, Inc. grew revenue faster over the last twelve months: −21.1% against −60.5%. Decoy Therapeutics Inc has the higher net margin (−698.8% vs −11,016.1%) and the higher return on invested capital (0.00% vs 0.00%). Across the 16 metrics below, Decoy Therapeutics Inc leads on 8 and VivoSim Labs, Inc. on 8.

Valuation

Metric DCOY VIVS Biotechnology median
P/E 0.01 n/m 8.50
P/S 0.30 7.48 9.71
P/B 0.14 n/m 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA 0.49 0.07 0.64
EV/Sales (3.48) (7.42) 9.21
Earnings yield 15,691.12% (2,793.75%) (33.15%)
Free cash flow yield (1,677.54%) (143.87%) (25.50%)

Profitability

Metric DCOY VIVS Biotechnology median
Gross margin 10.57% 100.00% 65.16%
Operating margin (706.88%) (10,116.96%) 0.00%
Net margin (698.79%) (11,016.07%) 0.00%
Free cash flow margin (432.43%) (1,014.29%) 0.00%
Return on equity (827.77%) (343.10%) (56.36%)
Return on assets (278.04%) (155.93%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric DCOY VIVS Biotechnology median
Revenue growth (TTM) (60.49%) (21.13%) 6.02%
EPS growth (last fiscal year) (85.66%) (214.71%) 30.26%
Revenue growth, 5-year CAGR 12.73% (43.10%) 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric DCOY VIVS Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 1.83 1.70 4.72
Net debt to EBITDA 0.85 0.45 0.96

Dividend

Metric DCOY VIVS Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric DCOY VIVS Biotechnology median
Market cap 2.93m 2.84m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack